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Background
Once-daily darunavir/ritonavir 800/100 mg is licensed
for first-line treatment and data are available in treat-
ment-experienced patients with no resistance-associated
mutations to darunavir. We designed an investigator
study to evaluate the switch to once-daily darunavir/
ritonavir 800/100 mg in treatment-experienced patients
with suppressed HIV-1 replication on a twice-daily rito-
navir-boosted protease-inhibitor (bid PI/r) containing
regimen, i.e. in a setting where genotypic resistance test
cannot be performed.
Methods
In this open-label, noncomparative, multicenter study,
patients on a bid PI/r-containing triple combination,
with suppressed viral replication, were switched to once-
daily darunavir/r 800/100 mg containing triple combina-
tion. The primary endpoint was the proportion of
patients with plasma HIV-RNA< 50 cp/ml 24 weeks
after the switch. Detailed darunavir pharmacokinetic
evaluation was performed at Week 4 (W4) and measure-
ment of HIV-RNA in seminal plasma at baseline and
W48 in a subset of patients.
Results
85 patients were enrolled. All had HIV-RNA<50 cp/ml
at screening with a median of 478 CD4/mm3 (range 40-
1559) and pre-exposure to a median of 2 PI (1-5). 61
patients were currently on lopinavir/r, 18 on fosampre-
navir/r, 4 on saquinavir/r and 2 on indinavir/r. At base-
line, 15/16 patients had a seminal HIV-RNA< 100 cp/ml
and 125 cp/ml for the remaining one. By intent-to-treat
analysis (missing=failure), 78/85 patients (92%, CI95
[83;96]) maintained an HIV-RNA<50 cp/ml at W24. 7
patients experienced protocol-defined treatment failure
between baseline and W24: 2 had confirmed viral
rebound (88 and 70 cp/ml), 1 discontinued study treat-
ment at W4 for adverse event, 3 withdrew their consent
and 1 was lost to follow-up. By on-treatment analysis,
78/80 patients (97%, CI95 [91;99]) maintained an HIV-
RNA<50 cp/ml at W24. At W4, the median area under
the darunavir plasma concentration-time curve mea-
sured in 11 patients was 61 380 ng.h/ml (IQR 25-75%
42 094-97 313), darunavir median trough concentration
1340 ng/ml (907-1830) and darunavir half-life was 12.2
h (8.3-13.7). Tolerability of once-daily darunavir/r 800/
100 mg was excellent.
Conclusion
In PI/r-experienced patients with suppressed viral repli-
cation on a bid PI/r-containing regimen, switching to
once-daily darunavir/r 800/100 mg containing regimen
was able to maintain suppression of viral replication and
was safe in this setting where genotypic resistance test
could not be performed.
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